Hematoxylin

Hematoxylin

SCHEMBL22203

Oc1cc2c(cc1O)[C@H]1c3ccc(O)c(O)c3OC[C@@]1(O)C2.[Fe]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.97
KDM4E B2RXH2 4/20 0.97
HPGD P15428 4/20 0.97
MAPK1 P28482 4/20 0.97
RECQL P46063 3/20 0.97
TDP1 Q9NUW8 3/20 0.97
ALDH1A1 P00352 3/20 0.97
CYP3A4 P08684 3/20 0.97
HSD17B10 Q99714 3/20 0.97
MET P08581 3/20 0.97
KIT P10721 3/20 0.97
FGFR1 P11362 3/20 0.97
SRC P12931 3/20 0.97
KDR P35968 3/20 0.97
G6PD P11413 2/20 0.97
L3MBTL1 Q9Y468 2/20 0.97
MEN1 O00255 2/20 0.97
ALOX15 P16050 2/20 0.97
KMT2A Q03164 2/20 0.97
NSD2 O96028 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Haematoxylin SCHEMBL29360033 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL29357236 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL1747 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL30101752 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL1784957 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL7026124 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL29363003 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL19654 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Haematoxylin SCHEMBL29366910 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL
Hematoxylin SCHEMBL30089789 0.99 MAPT (1.00) MAPTKDM4EHPGDMAPK1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 907 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117016479-A Construction method of solar dermatitis mouse model 中国人民解放军空军特色医学中心 2023-11-10 CN claimed
CN-116558928-A Red dye liquor for Masson trichromatic dyeing, reagent combination and method 图凌(杭州)生物医药有限公司 2023-08-08 CN claimed
CN-111812314-B Method for establishing complete Freund adjuvant induced frozen shoulder animal model 嘉兴市第二医院 2023-03-10 CN claimed
CN-114259327-A Method for reconstructing acetabular bone defect based on 3D printing 常州市第一人民医院 2022-04-01 CN claimed
CN-113425462-A Method for preparing metal cushion block for acetabular bone defect reconstruction through 3D printing 常州市第一人民医院 2021-09-24 CN claimed
CN-111812314-A Method for establishing complete Freund adjuvant induced frozen shoulder animal model 嘉兴市第二医院 2020-10-23 CN claimed
CN-107748260-B Experimental method for promoting tissue engineering prevascularization by umbilical cord mesenchymal stem cells 西安组织工程与再生医学研究所 2020-05-15 CN claimed
US-10572996-B2 Method and system for detecting pathological anomalies in a digital pathology image and method for annotating a tissue slide CONTEXTVISION AB (SE) 2020-02-25 US claimed
EP-3475874-A1 METHOD AND SYSTEM FOR DETECTING PATHOLOGICAL ANOMALIES IN A DIGITAL PATHOLOGY IMAGE AND METHOD FOR ANNOTATING A TISSUE SLIDE Contextvision AB (SE) 2019-05-01 EP claimed
CN-109187147-A A kind of dyeing of arterial wall ingredient and identification method 广州医科大学附属第医院 2019-01-11 CN claimed
US-20180112277-A1 SIGNAL DIRECTED DISSECTION TO INFORM CANCER THERAPY STRATEGY EXPRESSION PATHOLOGY, INC. 2018-04-26 US claimed
US-20170372471-A1 METHOD AND SYSTEM FOR DETECTING PATHOLOGICAL ANOMALIES IN A DIGITAL PATHOLOGY IMAGE AND METHOD FOR ANNOTATING A TISSUE SLIDE CONTEXTVISION AB (SE) 2017-12-28 US claimed
EP-1082611-A4 METHOD FOR STAINING BIOLOGICAL SPECIMENS BY COMBINING UNSTABLE REAGENTS ON A MICROSCOPE SLIDE VENTANA MED SYST INC (US) 2003-01-15 EP claimed
EP-1082611-A1 METHOD FOR STAINING BIOLOGICAL SPECIMENS BY COMBINING UNSTABLE REAGENTS ON A MICROSCOPE SLIDE VENTANA MEDICAL SYSTEMS, INC. (US) 2001-03-14 EP claimed
WO-1999063342-A1 METHOD FOR STAINING BIOLOGICAL SPECIMENS BY COMBINING UNSTABLE REAGENTS ON A MICROSCOPE SLIDE VENTANA MEDICAL SYSTEMS, INC. (US) 1999-12-09 WO claimed
US-5874315-A Method for staining stool parasites MERIDIAN DIAGNOSTICS, INC. (US) 1999-02-23 US claimed
US-20240240176-A1 PREVENTION OR TREATMENT OF MYOPATHY USING MIR-33B INHIBITOR KYOTO UNIVERSITY (JP) 2024-07-18 US disclosed
US-20240238346-A1 MYOCARDIAL WOUND HEALING POST ISCHEMIC INJURY TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2024-07-18 US disclosed
US-4435407-A ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS; IMMUNOMODULATORS CIBA-GEIGY CORPORATION (US) 1984-03-06 US disclosed
US-4256759-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS CIBA-GEIGY CORPORATION (US) 1981-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240240176-A1 PREVENTION OR TREATMENT OF MYOPATHY USING MIR-33B INHIBITOR MTPN, MYO3A, TNNI3 MAPT 1201/4885KDM4E 4195/4885HPGD 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.